Pipeline

In order to have the best first in class molecule to target dormant (persistent) bacteria we developed a proprietary screening platform to test and modify molecules.

A collaboration with the university of Rennes 1 in Pr. Felden’s Team (Bacterial Regulatory RNAs & Medicine), we developed news molecules that have the unique ability to eliminate pathogenic resistant bacteria. Moreover, these original molecules are able to eliminate the persisters (dormant bacteria) that are responsible of infectious relapses by targeting a specific feature of these bacteria. Based on these properties several molecules were designed and an original mechanism of action was discovered. We are now modifying the lead candidate OL20-01 on a proprietary platform, the only one able to screen persistent bacteria, in order to find the best in class molecule to cure patients.

After 20 years of research development and commercialization of products to fight against antibiotic resistance, the Olmix group has found and licensed a new molecule discovered in algae. This molecule has the property of boosting the immune system in immunodepressed preclinical models and thus could benefit to the patient to avoid nosocomial diseases. The molecule is being isolated, characterized and is now being processed toward preclinical development.